Free Trial
NASDAQ:CTXR

Citius Pharmaceuticals Q2 2023 Earnings Report

Citius Pharmaceuticals logo
$0.84 +0.02 (+2.67%)
Closing price 04:00 PM Eastern
Extended Trading
$0.85 +0.01 (+0.71%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Pharmaceuticals EPS Results

Actual EPS
-$1.75
Consensus EPS
-$1.00
Beat/Miss
Missed by -$0.75
One Year Ago EPS
N/A

Citius Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Citius Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, May 11, 2023
Conference Call Time
6:00PM ET

Upcoming Earnings

Citius Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Monday, May 12, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Citius Pharmaceuticals Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Citius Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Pharmaceuticals and other key companies, straight to your email.

About Citius Pharmaceuticals

Citius Pharmaceuticals (NASDAQ:CTXR), a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

View Citius Pharmaceuticals Profile

More Earnings Resources from MarketBeat